- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Potentially Undervalued Companies
Swiss Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED Oct 01, 2023
Companies with a Value score of at least 3, ordered by Value score
32 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| QGENQiagen | US$48.85 | 0% | 0% | US$9.2b | US$63.08 | PE18.9x | E5.9% | n/a | ||
| EVTEvotec | €27.76 | 0% | 1.1% | €3.3b | €40.99 | PS4.2x | E59.6% | n/a | ||
| LONNLonza Group | CHF425.60 | -1.5% | -13.3% | CHF31.6b | CHF627.41 | PE28x | E14.7% | 0.8% | ||
| BMYBristol-Myers Squibb | US$54.24 | 0% | 0% | US$121.3b | US$67.73 | PE15.2x | E14.2% | 3.9% | ||
| BIIBBiogen | US$222.00 | 0% | 0% | US$37.2b | US$282.90 | PE14x | E4.9% | n/a | ||
| TEVATeva Pharmaceutical Industries | US$7.85 | 0% | 0% | US$11.4b | US$8.16 | PB1.6x | E65.1% | 0% | ||
| 1102657GSK | UK£26.12 | 0% | -2.8% | UK£70.6b | UK£34.09 | PE13.8x | E8.9% | 5.7% | ||
| ROGRoche Holding | CHF250.45 | 0.4% | -22.2% | CHF202.0b | CHF313.40 | PE18.1x | E10.5% | 3.8% | ||
| GXIGerresheimer | €75.60 | 0% | 0% | €3.4b | €105.83 | PE32.2x | E23.7% | 1.3% | ||
| RORoche Holding | CHF269.40 | 0.7% | -30.2% | CHF202.0b | CHF337.12 | PE18.1x | E10.5% | 3.8% | ||
| ESFEurofins Scientific | €505.00 | 0% | 0% | €11.7b | €550.95 | PE20.1x | E4.7% | 1.7% | ||
| BSLNBasilea Pharmaceutica | CHF41.00 | -3.0% | -0.2% | CHF491.2m | CHF70.44 | PE8.7x | E19.1% | 0% | ||
| 2HQTilray Brands | US$46.28 | 0% | 0% | US$1.7b | US$56.82 | PS2.8x | E116.6% | n/a | ||
| LONNELonza Group | CHF428.90 | -0.8% | n/a | CHF31.6b | CHF632.28 | PE28x | E14.7% | 0.8% | ||
| NOVNNovartis | CHF93.87 | 1.5% | 23.5% | CHF194.1b | CHF102.53 | PE27.7x | E12.2% | 3.3% | ||
| 935700Gilead Sciences | US$68.48 | 0% | 10.5% | US$94.1b | US$82.84 | PE17.2x | E7.8% | 4.0% | ||
| 907582Amgen | US$226.36 | 0% | n/a | US$143.8b | US$221.00 | PE18x | E1.6% | 3.2% | ||
| BAYNBayer | €200.00 | 0% | 0% | €44.7b | €290.43 | PE30.8x | E25.4% | 5.3% | ||
| JCAREJoincare Pharmaceutical Group IndustryLtd | CN¥8.00 | 0% | -44.1% | CN¥23.1b | CN¥9.50 | PE15.2x | E16.9% | 1.5% | ||
| SFZNSiegfried Holding | CHF784.50 | 1.4% | 8.2% | CHF3.3b | CHF871.88 | PE22.4x | E10.2% | 0.4% | ||
| PPGNPolyPeptide Group | CHF16.72 | -2.5% | -41.9% | CHF550.8m | CHF20.52 | PS2x | E67.1% | 0% | ||
| NOVNEENovartis | CHF94.09 | 1.8% | 23.9% | CHF194.1b | CHF102.77 | PE27.7x | E12.2% | 3.3% | ||
| MERMERCK Kommanditgesellschaft auf Aktien | €168.09 | 0% | n/a | €79.8b | €191.28 | PE24.1x | E6.1% | 1.0% | ||
| MORMorphoSys | €102.00 | 0% | 0% | €882.6m | €124.83 | PE10x | E2.6% | n/a |